Press release - 11/08/2020 Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
CeGat GmbH - 06/08/2020 Specific coronavirus antibody test for all Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
Anniversary - 12/12/2018 15 years of BIOPRO: Pooling competencies – pushing innovations This is the leitmotif of BIOPRO Baden-Württemberg GmbH, which was founded in 2003. 15 years is a good time to pause for a moment and take a look at BIOPRO’s work and achievements. As a central point of contact and wholly-owned subsidiary of the Baden-Württemberg government whose main objective is to promote networking, BIOPRO knows only too well that progress is not made alone, but in collaboration with others.https://www.gesundheitsindustrie-bw.de/en/article/press-release/15-years-of-biopro-pooling-competencies-pushing-innovations
Article - 30/10/2018 Eucor – bringing the European Campus to life Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences. https://www.gesundheitsindustrie-bw.de/en/article/news/eucor-bringing-the-european-campus-to-life
Press release - 27/09/2018 One hundred percent success Two Clusters of Excellence for the University of Freiburg: Biological Signalling Studies and Bioinspired Materials Research. It is a major boost to cutting-edge research in Freiburg: in the current Excellence Strategy competition, scientists at the University of Freiburg have been granted two Clusters of Excellence, CIBSS – Centre for Integrative Biological Signalling Studies, and livMatS – Living, Adaptive and Energy-autonomous Materials…https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-hundred-percent-success
Industry report 2018 - 27/09/2018 The healthcare industry – the innovation driver of the 21st century: opportunities and challenges BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-healthcare-industry-the-innovation-driver-of-the-21st-century
Press release - 27/07/2018 KIT Takes the Next Step: Federal and State Ministries Determined to Push KIT’s Further Development To further support and develop the scientific capacity of Karlsruhe Institute of Technology (KIT), the federal and state governments are determined to take the courageous merger of 2009 to the next level. During their joint visit of KIT today, Federal Minister of Education and Research Anja Karliczek and the Baden-Württemberg Minister for Science, Research and the Arts Theresia Bauer agreed on the next steps. https://www.gesundheitsindustrie-bw.de/en/article/press-release/kit-takes-the-next-step-federal-and-state-ministries-determined-to-push-kits-further-development
Article - 10/10/2016 Teva plans the large-scale production of monoclonal antibodies in Ulm Teva is investing heavily in its biotechnological production site in Ulm. On behalf of BIOPRO Baden-Württemberg, Walter Pytlik spoke with Dr. Hermann Allgaier, CEO of Teva Biotech, about the importance of biotechnology for the Group and about Teva in general. The company is headquartered in Israel.https://www.gesundheitsindustrie-bw.de/en/article/news/teva-plans-the-large-scale-production-of-monoclonal-antibodies-in-ulm
Business location Baden-Württemberg - 29/09/2016 "Well done - biotechnology as the driver of innovations in Baden-Württemberg" Eight members of the Bundestag from Baden-Württemberg attended the Parliamentary Breakfast on 21st September 2016 in Berlin where information was presented on the performance of the biotechnology sector in Baden-Württemberg. The politicians also discussed with entrepreneurs ways of improving general conditions in the sector.https://www.gesundheitsindustrie-bw.de/en/article/press-release/clever-gemacht-biotechnologie-als-innovationsmotor-in-baden-wuerttemberg
Press release - 03/11/2015 CureVac raises $110 Million in a private placement CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
Press release - 30/09/2015 Vetter Embarks on a 300 Million Euro Investment Strategy for Further Development To its Manufacturing Sites and to make available Additional Manufacturing Capacities Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug products, the company will invest approximately 300 million euros to expand and upgrade its manufacturing facilities over an estimated five-year period. As a leading contract development and manufacturing organization, Vetter is continuously developing its manufacturing sites and techniques to prepare them for future needs and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-embarks-on-a-300-million-euro-investment-strategy
Article - 15/06/2015 Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients Since January 2015, Tübingen has been home to a Centre for Personalised Medicine (ZPM). Twenty-three institutes and hospitals have joined forces to improve diagnosis of disease and develop individualised treatments for patients with a variety of diseases. In parallel, the centre also develops new diagnostic strategies. This means, for example, that data derived from the analysis of the entire genetic material of cells, proteins and metabolic…https://www.gesundheitsindustrie-bw.de/en/article/news/centre-for-personalised-medicine-in-tuebingen-developing-tailor-made-treatments-for-patients
Press release - 27/10/2011 Bruce Edgar and Andreas Trumpp acknowledged for achievements in life sciences Molecular biologist Prof. Dr. Bruce Edgar and cancer and stem cell researcher Prof. Dr. Andreas Trumpp have been elected to EMBO membership in recognition of their outstanding scientific contribution. EMBO’s approximately 1,500 members are leaders in their research fields around the world.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bruce-edgar-and-andreas-trumpp-acknowledged-for-achievements-in-life-sciences
Press release - 23/07/2011 Innovative strength in Baden-Württemberg The Baden-Württemberg Ministry of Finance and Economics presented the results of two studies that evaluated the innovative strength of Baden-Württemberg in comparison to other regions around the world. The studies were carried out by the University of Hohenheim and the independent research institute BAK Basel Economics AG BAK Basel on behalf of the Baden-Württemberg Ministry of Finance and Economics and they were financed by the Baden-Württemberg…https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-strength-in-baden-wuerttemberg
Article - 18/01/2011 Innovation hotspots In December 2010, the German and Israeli Ministers of Economics, Rainer Brüderle and Binyamin Ben-Eliezer, jointly opened the German-Israeli Innovation Day. The motto of the annual conference organised by the German-Israeli Life Sciences Committee in Heidelberg was “New ideas for a healthier world”. The conference enabled German participants to expand and reinforce their contacts with Israeli companies based on the long-standing cooperation…https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-hotspots
Press release - 09/01/2011 Baden-Württemberg Research and Development Monitor In 2007 the RD expenditures of industrial research institutions universities and publicly funded RD institutions reached a record high. As much as one quarter of German RD expenditures were incurred in Baden-Württemberg which shows that Baden-Württemberg is further expanding its strong position. The majority of the research in Baden-Württemberg is carried out by industrial companies. https://www.gesundheitsindustrie-bw.de/en/article/press-release/baden-wuerttemberg-research-and-development-monitor
Press release - 05/12/2010 Baden-Württemberg ahead of all other German states in terms of health research Health research for the benefit of individuals is of great importance in Baden-Württemberg. Baden-Württemberg researchers are among the best in the field of health research both on a national and international level. This is reflected in the success achieved by universities research institutions and university hospitals in competitions said Minister President Stefan Mappus and Dr. Dietrich Birk Secretary of State in the Ministry of Science…https://www.gesundheitsindustrie-bw.de/en/article/press-release/baden-wuerttemberg-ahead-of-all-other-german-states-in-terms-of-health-research
Press release - 07/11/2010 CHE ExcellenceRanking 2010 Top results were achieved by the Universities of Freiburg Heidelberg Karlsruhe Stuttgart and Tübingen in the subjects of biology chemistry mathematics and physics. With these achievements five of the 26 German universities ranked in the Excellence Group come from Germanys southwest.https://www.gesundheitsindustrie-bw.de/en/article/press-release/che-excellenceranking-2010
Article - 03/10/2010 ColepCCL: A creative hub to prepare for the company’s move into the life sciences ColepCCL Rapid-Spray a ColepCLL subsidiary based in Laupheim Germany has made a name for itself as the largest European contract filler of aerosols. However ColepCLL which employs around 3500 people in five countries is now planning to open up new fields of activity in the life sciences area.https://www.gesundheitsindustrie-bw.de/en/article/news/colepccl-a-creative-hub-to-prepare-for-the-company-s-move-into-the-life-sciences
Press release - 25/06/2010 Vetter to invest further millions in the construction of a modern centre for visual inspection and logistics in Ravensburg Ravensburg-based Vetter is expanding further. Last Friday, Vetter, a specialist in aseptically pre-filled drug-delivery systems, held a ceremony to break the ground for the construction of a new centre for visual inspection and logistics. Together with representatives from politics and industry, the company’s executives broke the ground for the new facility, which is estimated to cost more than 30 million euros. The construction of the new centre…https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-to-invest-further-millions-in-the-construction-of-a-modern-centre-for-visual-inspection-and-l
Press release - 23/12/2009 ratiopharm to maintain 2008 sales and EBITDA levels The Ulm-based generics producer ratiopharm, which is up for sale, has announced that its earnings before interest, taxes, depreciation and amortisation (EBITDA) will reach 300 million euros for the fiscal year 2009, which is roughly the same as the previous year’s level. According to the company’s CEO, Oliver Windholz, the company's revenue is predicted to be around €1.6 billion, which is also close to its 2008 level.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ratiopharm-to-maintain-2008-sales-and-ebitda-levels
Press release - 29/06/2009 Vetter strengthens Ravensburg company site Vetter Pharma, a leading provider of aseptically pre-filled injection systems, has completed the installation of several new automatic packaging lines at the company’s new packaging services facility. The packaging facility allows Vetter to package its injection systems for delivery to its clients. The building, which cost 20 million euros to build, has room for 200 employees. https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-strengthens-ravensburg-company-site
Press release - 30/04/2009 Prize for more efficient radiotherapy for leukaemia Peter Kletting’s model can be used to irradiate the tumour cells of leukaemia patients more accurately, reduce potential side effects and increase the chances of therapeutic success. The scientist from the Department of Nuclear Medicine at the University Hospital of Ulm has been awarded the Society for Nuclear Medicine Covidien Award that comes with a purse of 7,500 euros. https://www.gesundheitsindustrie-bw.de/en/article/press-release/prize-for-more-efficient-radiotherapy-for-leukaemia